Searching…
Nov 9, 2024 · Background NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF)/MET receptor system (Moebius and Church, 2023). HGF promotes proliferation and surv...
Karstens AJ, Christianson TJ, Lundt ES, Machulda MM, Mielke MM, Fields JA, Kremers WK, Graff-Radford J, Vemuri P, Jack CR Jr, Knopman DS, Petersen RC, Stricker NH. Mayo normative studies: regression-based normative da...
Jul 24, 2024 · Schneider AL, Pike JR, Elser H, Coresh J, Mosley TH, Diaz-Arrastia R, Gottesman RF. Traumatic brain injury and cognitive change over 30 years among community-dwelling older adults. Alzheimers Dement. 20...
Hu C, Yu D, Sun X, Zhang M, Wang L, Qin H. The prevalence and progression of mild cognitive impairment among clinic and community populations: a systematic review and meta-analysis. Int Psychogeriatr. 2017 Oct;29 (10)...
Apr 17, 2012 · Type 2 diabetes has been identified as one of the risk factors for AD. Two papers analyzing insulin signaling in the brains of Alzheimer’s disease (AD) patients have been published back to back in the J...
Background Pridopidine, formerly called huntexil, is a selective agonist of the sigma1 receptor, a molecular chaperone located in the endoplasmic reticulum in association with mitochondria. Sigma1Rs are highly express...
www.alzforum.org
Background ION363 is an antisense oligonucleotide designed to reduce the production of a mutated, neurotoxic form of the Fused in Sarcoma (FUS) protein. FUS mutations have been identified as a cause of familial ALS an...
Brain Res. 2004 Aug 13;1017 (1-2):130-6. PubMed. Sasmita AO, Ong EC, Nazarenko T, Mao S, Komarek L, Thalmann M, Hantakova V, Spieth L, Berghoff SA, Barr HJ, Hingerl M, Börensen F, Hirrlinger J, Simons M, Stevens B, De...
Following up on its October surprise, Biogen showed more data at the Clinical Trials in Alzheimer’s Disease conference, arguing that disparities in drug exposure explained the puzzlingly different outcomes in its one ...
